Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 4/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.44 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.44 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.44 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.44 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.44 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4598237 | 0.92 | PSEN1 (0.49) | MEN1GAAKMT2AL3MBTL1LMNA | |
| SCHEMBL1047069 | 0.88 | PPARA (0.56) | ELANEMEN1GAAKMT2AL3MBTL1 | |
| SCHEMBL7768560 | 0.85 | PTPN1 (0.55) | ELANEMEN1GAAKMT2AL3MBTL1 | |
| SCHEMBL2611828 | 0.84 | MAPT (0.47) | ESR1LMNAMAPTHPGDPSEN1 | |
| SCHEMBL7335964 | 0.83 | L3MBTL1 (0.56) | MEN1GAAKMT2AL3MBTL1LMNA | |
| SCHEMBL10421964 | 0.83 | PTGS2 (0.51) | ELANEGAAESR1ESR2LMNA | |
| SCHEMBL1964630 | 0.83 | PLA2G4B (0.61) | PKMHTTPTPN1 | |
| SCHEMBL6229185 | 0.81 | PARP10 (0.57) | MEN1GAAKMT2AL3MBTL1MAPT | |
| SCHEMBL1964131 | 0.81 | PSEN1 (0.46) | ELANEMEN1GAAKMT2AL3MBTL1 | |
| 4-Vinylphenol SCHEMBL3332947 | 0.81 | MEN1 (0.47) | MEN1GAAKMT2AL3MBTL1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110021471-A1 | REDUCING Abeta42 LEVELS AND Abeta AGGREGATION | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2011-01-27 | — | — | US | disclosed |
| WO-2009059239-A2 | REDUCING Aβ42 LEVELS AND Aβ AGGREGATION | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2009-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021471-A1 | REDUCING Abeta42 LEVELS AND Abeta AGGREGATION | APP, BACE1, GAP43 | ELANE 2281/4885MEN1 2435/4885GAA 535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.